$OraSure Technologies (OSUR.US)$
OraSure Unveils Major $40M Stock Buyback: Management Signals Strong Confidence

$OraSure Technologies (OSUR.US)$
OraSure Announces $40 Million Stock Repurchase Program
Monday, 24th March at 7:30 am
BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the "Company") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on ...

$OraSure Technologies (OSUR.US)$ Reuters· just
OraSure Announces $40 Million Stock Repurchase Program

$OraSure Technologies (OSUR.US)$
OraQuick® HIV Self-Test Now Approved for Use in Adolescents
Tuesday, 7th January at 7:05 am
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older.
According to the most recent data available from t...

$OraSure Technologies (OSUR.US)$
Still, it doesn't look ready quite yet.

$OraSure Technologies (OSUR.US)$
OraSure Technologies Acquires Sherlock Biosciences
Thursday, 19th December at 4:02 pm
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.
This acquisition expands OraS...

$OraSure Technologies (OSUR.US)$
Take a look. See if you like it.

$OraSure Technologies (OSUR.US)$
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
OraSure Technologies (NASDAQ: OSUR) has received a federal contract through the Rapid Response Partnership Vehicle (RRPV) to develop a Marburg Virus Disease (MVD) rapid antigen test. The initial contract is valued at $7.5 million over multiple years, with potential value up to $11 million. The funding from BARDA aims to achieve FDA 510(k) clearance for a single-use lateral f...